Artwork

Innhold levert av Qualio. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av Qualio eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.
Player FM - Podcast-app
Gå frakoblet med Player FM -appen!

How Artificial Intelligence Can Accelerate Drug Discovery and Bridge the Translational Gap with Jo Varshney of VeriSIM Life

17:04
 
Del
 

Manage episode 329919821 series 2833485
Innhold levert av Qualio. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av Qualio eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.

The average cost of developing a new drug is estimated at over $2 billion. Roughly 10% of pre-clinical drugs ever make it to human trials. And each year, $50 billion is “misspent” in the trial & error method of research and development. An AI-enabled “decision engine” could help researchers find cures to rare diseases, bridge the translational gap between animal models to human systems, and move faster in drug development reducing associated R&D costs.

Today on the show we chat with Jo Varshney, the founder of VeriSIM Life, about the AI-enabled technology that is cutting the time for drug development in half. Searching for a drug candidate for bone cancer led Dr. Varshney to tackle the challenges of better predicting outcomes, improving methods for drug discovery, and building models closer to human systems.

About Jo Varshney and VeriSIM Life
Dr. Jo Varshney is a multi-disciplinary and celebrated leader in veterinary & human health development. She is the founder and CEO of VeriSIM Life, which is building AI-enabled biosimulation technology to empower researchers to predict how potential drug candidates will interact in animal models. Dr. Varshney holds a Ph.D. in Comparative Oncology and Genomics from the University of Minnesota, a Master's Degree in Translational Pathobiology & Bioinformatics from Penn State University, and a Doctorate of Veterinary Medicine from the College of Veterinary Science & Animal Husbandry. She serves as a Scientific Advisor at SVAI, a San Francisco-based non-profit organization promoting education and cooperative research at the intersection of computational and life sciences.
Links:

VeriSIM Life
LinkedIn | Jo Varshney
Genomics Hackathon
Wikipedia | Drug Discovery
Wikipedia | The Translational Gap
Qualio Website
Previous episodes: https://www.qualio.com/from-lab-to-launch-podcast
Apply to be on the show: https://forms.gle/uUH2YtCFxJHrVGeL8

Music by keldez

Qualio website:
https://www.qualio.com/

Previous episodes:
https://www.qualio.com/from-lab-to-launch-podcast

Apply to be on the show:
https://forms.gle/uUH2YtCFxJHrVGeL8

Music by keldez

  continue reading

101 episoder

Artwork
iconDel
 
Manage episode 329919821 series 2833485
Innhold levert av Qualio. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av Qualio eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.

The average cost of developing a new drug is estimated at over $2 billion. Roughly 10% of pre-clinical drugs ever make it to human trials. And each year, $50 billion is “misspent” in the trial & error method of research and development. An AI-enabled “decision engine” could help researchers find cures to rare diseases, bridge the translational gap between animal models to human systems, and move faster in drug development reducing associated R&D costs.

Today on the show we chat with Jo Varshney, the founder of VeriSIM Life, about the AI-enabled technology that is cutting the time for drug development in half. Searching for a drug candidate for bone cancer led Dr. Varshney to tackle the challenges of better predicting outcomes, improving methods for drug discovery, and building models closer to human systems.

About Jo Varshney and VeriSIM Life
Dr. Jo Varshney is a multi-disciplinary and celebrated leader in veterinary & human health development. She is the founder and CEO of VeriSIM Life, which is building AI-enabled biosimulation technology to empower researchers to predict how potential drug candidates will interact in animal models. Dr. Varshney holds a Ph.D. in Comparative Oncology and Genomics from the University of Minnesota, a Master's Degree in Translational Pathobiology & Bioinformatics from Penn State University, and a Doctorate of Veterinary Medicine from the College of Veterinary Science & Animal Husbandry. She serves as a Scientific Advisor at SVAI, a San Francisco-based non-profit organization promoting education and cooperative research at the intersection of computational and life sciences.
Links:

VeriSIM Life
LinkedIn | Jo Varshney
Genomics Hackathon
Wikipedia | Drug Discovery
Wikipedia | The Translational Gap
Qualio Website
Previous episodes: https://www.qualio.com/from-lab-to-launch-podcast
Apply to be on the show: https://forms.gle/uUH2YtCFxJHrVGeL8

Music by keldez

Qualio website:
https://www.qualio.com/

Previous episodes:
https://www.qualio.com/from-lab-to-launch-podcast

Apply to be on the show:
https://forms.gle/uUH2YtCFxJHrVGeL8

Music by keldez

  continue reading

101 episoder

כל הפרקים

×
 
Loading …

Velkommen til Player FM!

Player FM scanner netter for høykvalitets podcaster som du kan nyte nå. Det er den beste podcastappen og fungerer på Android, iPhone og internett. Registrer deg for å synkronisere abonnement på flere enheter.

 

Hurtigreferanseguide

Copyright 2024 | Sitemap | Personvern | Vilkår for bruk | | opphavsrett